Tissium Raises €60M for Medtech Commercialization

Tissium, a medical technology innovator, has successfully secured a substantial €60 million financing package, signaling a pivotal moment as the company transitions into its commercial phase. This significant funding infusion is earmarked to accelerate the market rollout of its groundbreaking tissue reconstruction solutions and advance its robust clinical development pipeline.

The financing comprises two key components: a recently concluded €30 million Series D2 equity round, bolstered by a diverse group of international and U.S.-based investors, and a substantial €30 million financing facility extended by the European Investment Bank (EIB). This dual approach provides Tissium with both strategic equity backing and flexible debt financing, crucial for navigating the complexities of commercial expansion and ongoing research.

This capital injection arrives on the heels of a transformative period for Tissium, notably marked by the U.S. Food and Drug Administration's (FDA) marketing authorization for its flagship product, COAPTIUM CONNECT. The company has already established a presence in the U.S. commercial market, a critical step in leveraging its proprietary biomorphic programmable polymer technology. The funds will directly support the commercial execution of COAPTIUM CONNECT and fuel the advancement of Tissium's pipeline, which targets significant unmet needs in areas such as atraumatic nerve repair, hernia repair, and cardiovascular applications.

The EIB facility, aligned with the objectives of the InvestEU program, underscores European support for transformative healthcare technologies. This facility is structured in three €10 million tranches, contingent upon achieving specific commercial, clinical, and financing milestones. Tissium anticipates drawing the initial €10 million tranche by the close of June 2026. This structure offers Tissium considerable financial agility, allowing it to manage its growth trajectory effectively.

The Series D2 round, finalized at the end of 2025, not only strengthened Tissium's financial position but also enhanced its shareholder base with contributions from prominent new and existing backers. This equity infusion is vital for scaling operations, supporting ongoing clinical trials, and further developing its innovative polymer platform. The company's strategic vision centers on building upon its successful transition from a research-focused entity to a revenue-generating medical technology enterprise.

Christophe Bancel, CEO and Co-Founder of Tissium, emphasized the significance of this financing, stating, “This financing marks an important milestone in Tissium’s evolution. Following the FDA marketing authorization of COAPTIUM® CONNECT, we are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform. The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”

The broader medical device market, particularly in reconstructive surgery and advanced biomaterials, is experiencing robust growth, driven by an aging population and increasing demand for minimally invasive procedures. Tissium's focus on programmable polymers offers a unique value proposition, potentially disrupting traditional surgical repair methods and improving patient outcomes. This funding positions the company to capitalize on these market dynamics and solidify its competitive advantage.